Make your bio(pharma) IP investment ready

Whether you’re scaling or planning your next strategic step, these sessions will share practical insights to help future‑proof your IP and strengthen your investment story.

Episode 1: How to build a resilient IP portfolio in the (bio)pharma sector

How you structure and protect intellectual property can be critical to securing investment in the biopharma sector. In this first episode of EIP’s LinkedIn Live series, our biopharma IP experts examine what investors look for in an investment‑ready biopharma IP portfolio, and how companies can position their patent strategy to support funding, partnerships, and long‑term value creation.

Gareth Probert, Head of Biopharma & Chemistry, and Tim Belcher, Partner in EIP’s Biopharma team, focus on three core pillars that consistently influence investor due diligence and valuation: who owns the IP, what should be protected, and when patent applications should be filed.
‍

Episode 2: Strategic IP moves to consider when preparing for an investment round

In this second episode of EIP’s LinkedIn Live series, Tim Belcher and Rob Barker explore the strategic IP decisions biopharma companies should make ahead of investment rounds. From aligning patent strategy with investor expectations to managing disclosures, due diligence, freedom‑to‑operate, and data rooms, the session outlines practical steps to reduce risk, build credibility, and position IP as a core driver of valuation and deal success.

‍

Episode 3: A forward look at the 2026 (bio)pharma landscape and what it means for your business and IP strategy

In the final episode of EIP’s LinkedIn Live series, Gareth Probert and Robert Barker explore what the year ahead holds for biopharma investment and IP strategy. The discussion highlights renewed optimism and increasing deal activity as the sector emerges from a period of reduced investment. With major pharmaceutical companies facing significant patent cliffs, attention is shifting towards external innovation, particularly later‑stage and proof‑of‑concept assets that can replenish pipelines quickly.